Skip to main content

Table 5 “Concomitant LABA and ICS users” stratified by inhaler type for the years 2004 to 2008: “Combined Inhalers”, “Separate Inhalers”, “Combinations”

From: Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial

  Year
  2004 2005 2006 2007 2008
Combined inhalers [fixed LABA/ICS] 101,814 (82.2%) 126,347 (82.7%) 126,301 (82.9%) 145,464 (84.5%) 151,784 (85.7%)
Separate inhalers [non-fixed LABA/ICS] 15,044 (12.1%) 18,490 (12.1%) 17,767 (11.7%) 17,930 (10.4%) 16,750 (9.5%)
Combinations 7,015 (5.7%) 8,020 (5.2%) 8,350 (5.5%) 8,831 (5.1%) 8,625 (4.9%)